Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported strong revenue growth in 2013, primarily driven by its flagship product, EYLEA. Net revenues reached $2.1 billion, a significant increase from $1.38 billion in 2012, showcasing EYLEA's rapid market penetration in ophthalmology for wet AMD and macular edema. The company's product pipeline is robust, with 16 product candidates in clinical development, many of which are being developed in collaboration with major pharmaceutical partners like Sanofi and Bayer HealthCare. Key pipeline candidates include those for rheumatoid arthritis (sarilumab), LDL cholesterol reduction (alirocumab), and various allergic and immune conditions (dupilumab), indicating a diversified future revenue potential beyond EYLEA. While Regeneron achieved profitability in 2012 and maintained it in 2013, significant investment in research and development continues to be a primary focus, underscoring the company's commitment to innovation and long-term growth.
Financial Highlights
47 data points| Revenue | $2.10B |
| Cost of Revenue | $118.05M |
| Gross Profit | $1.99B |
| R&D Expenses | $859.95M |
| SG&A Expenses | $346.39M |
| Operating Expenses | $1.36B |
| Operating Income | $743.05M |
| Interest Expense | $46.44M |
| Net Income | $413.74M |
| EPS (Basic) | $4.23 |
| EPS (Diluted) | $3.72 |
| Shares Outstanding (Basic) | 97.92M |
| Shares Outstanding (Diluted) | 111.29M |
Key Highlights
- 1EYLEA continued its strong sales trajectory, with U.S. net product sales reaching $1.41 billion in 2013, representing a substantial increase from $837.9 million in 2012.
- 2Total revenues for 2013 surged to $2.10 billion, a significant jump from $1.38 billion in 2012, demonstrating robust top-line growth.
- 3Regeneron reported net income of $424.4 million in 2013, translating to $3.81 per diluted share, indicating continued profitability.
- 4The company has an extensive pipeline with 16 product candidates in clinical development, including promising antibody-based therapies for major indications like rheumatoid arthritis, cholesterol management, and allergic conditions.
- 5Collaborations with Sanofi and Bayer HealthCare are crucial for global development and commercialization, providing significant funding and market access for key products like EYLEA and ZALTRAP.
- 6Investment in research and development remains high, with R&D expenses increasing to $860 million in 2013, reflecting the company's strategy to fuel future growth through innovation.